Opexa Therapeutics, Inc.·4

Sep 26, 8:57 PM ET

Opexa Therapeutics, Inc. 4

4 · Opexa Therapeutics, Inc. · Filed Sep 26, 2013

Insider Transaction Report

Form 4
Period: 2013-09-24
Transactions
  • Conversion

    Common Stock

    2013-09-24$1.91/sh+269,182$514,138518,708 total(indirect: See footnote.)
  • Conversion

    Convertible Promissory Note

    2013-09-240 total(indirect: See footnote.)
    Exercise: $1.91From: 2012-07-25Exp: 2014-07-25Common Stock (269,182 underlying)
Holdings
  • Common Stock

    10,913
Footnotes (2)
  • [F1]Held by Alkek & Williams Ventures, Ltd. ("Ventures"). Chaswil, Ltd. ("Chaswil") is the investment manager of Ventures and holds voting power and investment power with respect to the Issuer securities held by Ventures. Mr. Seaman is a registered principal of Chaswil and has shared voting power and/or investment power with respect to the Issuer securities held by Ventures. Mr. Seaman disclaims beneficial ownership of the shares held by Ventures except to the extent of any pecuniary interest therein.
  • [F2]On September 23, 2013, the Note was amended to provide that in addition to the existing conversion arrangements (i.e., convertible at the election of the Holder or the Issuer into Convertible Preferred Stock at a conversion price of $100), the Note also became convertible at the Issuer's election directly into Common Stock (rather than any intermediate conversion to Convertible Preferred Stock) at the most recent closing market price (subject to a market price range) of the Common Stock at the time of any election by the Issuer to convert the Note directly into Common Stock. On September 24, 2013, the Issuer converted the principal balance of the Note plus accrued interest into 269,182 shares of Common Stock at a conversion price of $1.91.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4